Chief strategy officer, Astellas Pharma
Appears in 1 story
Overseeing the deal from Astellas' side
A Melbourne drug developer founded by two researchers and funded largely from their own pockets has signed one of the biggest preclinical drug deals to come out of Australia. Japanese drugmaker Astellas now holds the exclusive option to license Audax Biosciences' lead cancer therapy worldwide, a package worth up to $1.34 billion before royalties.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
